Literature DB >> 2683997

Immunosuppression by melanoma cells as a factor in the generation of metastatic disease.

A J Cochran1, D R Wen, Z Farzad, M A Stene, W McBride, A M Lana, D S Hoon, D L Morton.   

Abstract

Studies of the regional nodes (RLN) of melanoma patients, using immunohistology with anti-S-100 protein and monoclonal antibodies have shown occult tumor cells (OTC) in nodes ostensibly tumor-free by H&E staining. OTC were demonstrated in 14% of Stage I patients, mainly those with deep, thick primaries and 30% of Stage II patients, mainly those with at least 3 tumor-positive nodes on H&E. The nodes containing OTC are those nearest to tumor on the direct lymphatic pathway (dye studies). Parallel studies show nodes in the same position to be immune suppressed (histology, immunohistology, response to mitogens, alloantigens and lymphokines) and to contain many suppressor T cells (Con-A). Melanoma-derived materials (gangliosides, prostaglandins, lipoprotein antigens) downregulate lymphocyte and macrophage functions, providing a possible mechanism for the suppressed function of nodes near tumor, a suppression that may facilitate tumor cells as evidenced by the survival of OTC.

Entities:  

Mesh:

Year:  1989        PMID: 2683997

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Surgery and sentinel lymph node biopsy.

Authors:  Mark B Faries; Donald L Morton
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 2.  The lymph node pre-metastatic niche.

Authors:  Jonathan P Sleeman
Journal:  J Mol Med (Berl)       Date:  2015-11       Impact factor: 4.599

3.  An analysis of lymphocyte subsets in the regional lymph nodes of patients with papillary thyroid carcinoma.

Authors:  K Sugino
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 4.  Elective lymph node dissection for melanoma: two perspectives.

Authors:  W H McCarthy; H M Shaw; N Cascinelli; M Santinami; F Belli
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

5.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

6.  Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Authors:  Zhiqiang Xu; Michelle A Hurchla; Hongju Deng; Ozge Uluçkan; Fang Bu; Andrew Berdy; Mark C Eagleton; Emanuela A Heller; Desiree H Floyd; Wessel P Dirksen; Sherry Shu; Yuetsu Tanaka; Soledad A Fernandez; Thomas J Rosol; Katherine N Weilbaecher
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

7.  Tc-99m diphosphonate as a potential radiotracer to detect sentinel lymph nodes in patients with breast cancer.

Authors:  You-Jung Yang; Sung-Jig Lim; Jeong-Yoon Song
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

8.  The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

Authors:  Paolo A Ascierto; Mariaelena Capone; Walter J Urba; Carlo B Bifulco; Gerardo Botti; Alessandro Lugli; Francesco M Marincola; Gennaro Ciliberto; Jérôme Galon; Bernard A Fox
Journal:  J Transl Med       Date:  2013-03-03       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.